Olumiant (Baricitinib)

Phase 3
Intervention Type
Oral Drug
Funder Type
Organization | University

Drug Details

Olumiant (Baricitinib) is a type of drug known as a janus kinase, or JAK, inhibitor, which generally works by blocking proteins that play a role in inflammation. 

Study Purpose

Multiple studies are taking place involving this drug. The reason for the studies is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.

Find a Clinical Trial


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >